美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Abivax S.A.

113.58

-5.0600-4.27%

盤前：112.48-1.1000-0.97%05:54 EDT

成交量：115.67萬

成交額：1.32億

市值：98.88億

市盈率：-21.77

高：117.14

開：116.66

低：113.20

收：118.64

52周最高：148.83

52周最低：69.81

股本：8,705.45萬

流通股本：7,645.54萬

量比：1.10

換手率：1.51%

股息：- -

股息率：- -

每股收益(TTM):-5.2168

每股收益(LYR):-5.6758

淨資產收益率：-157.07%

總資產收益率：-44.65%

市淨率：19.95

市盈率(LYR):-20.01

資料載入中...

總覽公司新聞資訊公告

異動解讀｜Abivax S.A.盤中下跌5.15%，三期試驗安全性爭議未消致反彈行情受阻

異動解讀｜Abivax S.A.盤中上漲5.15%，三期試驗安全性爭議消化後股價延續技術性反彈

異動解讀｜Abivax S.A.盤中上漲5.03%，三期試驗安全性爭議消化後股價延續技術性反彈

異動解讀｜Abivax S.A.盤中下跌5.27%，三期試驗癌症病例安全性爭議疊加證券欺詐調查持續壓制股價

異動解讀｜Abivax S.A.盤中下跌5.32%，三期試驗癌症病例安全性爭議持續壓制股價

異動解讀｜Abivax S.A.盤中下跌5.49%，三期試驗癌症病例安全性爭議持續壓制股價

異動解讀｜Abivax S.A.盤中上漲5.65%，三期試驗因癌症病例引發暴跌後延續反彈

異動解讀｜Abivax S.A.盤中上漲16.03%，三期試驗因癌症病例引發暴跌後盤中延續反彈

異動解讀｜Abivax S.A.盤前上漲6.21%，三期試驗因癌症病例引發暴跌後盤前延續反彈

異動解讀｜Abivax S.A.夜盤上漲5.28%，三期試驗因癌症病例引發暴跌後盤後小幅回升

異動解讀｜Abivax S.A.盤後上漲5.12%，三期試驗因癌症病例引發暴跌後盤後小幅回升

異動解讀｜Abivax S.A.盤中下跌40.7%，三期試驗數據因癌症病例複雜化引發市場恐慌

異動解讀｜Abivax S.A.盤前下跌30.12%，三期試驗數據因癌症病例複雜化引發市場恐慌

異動解讀｜Abivax S.A.夜盤下跌25.58%，Obefazimod三期維持試驗達主要終點但市場反應消極

異動解讀｜Abivax S.A.盤後上漲31.08%，報170.0美元

異動解讀｜Abivax S.A.盤中上漲5.03%，財報披露現金儲備充裕提振信心

異動解讀 | 現金儲備充裕緩解研發擔憂，Abivax S.A.盤前大漲8.26%

異動解讀｜Abivax S.A.盤前上漲9.06%，財報披露現金儲備充裕提振信心

異動解讀 | 現金儲備充裕緩解研發擔憂，Abivax S.A.夜盤大漲9.85%

異動解讀｜Abivax S.A.夜盤上漲5.8%，財報披露現金儲備充裕提振信心

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/ABVX/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ABVX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABVX\",,,,,undefined,":{"symbol":"ABVX","market":"US","secType":"STK","nameCN":"Abivax S.A.","latestPrice":113.58,"timestamp":1789416000000,"preClose":118.64,"halted":0,"volume":1156685,"hourTrading":{"tag":"盘前","latestPrice":112.48,"preClose":113.58,"latestTime":"05:54 EDT","volume":765,"amount":85825.44945,"timestamp":1789466090812,"change":-1.1,"changeRate":-0.009685,"amplitude":0.005459},"delay":0,"changeRate":-0.04265003371544169,"floatShares":76455400,"shares":87054500,"eps":-5.216782,"marketStatus":"盤前交易","change":-5.06,"latestTime":"09-15 06:21:57 EDT","open":116.66,"high":117.135,"low":113.2,"amount":132429363.02455,"amplitude":0.033168,"askPrice":112.67,"askSize":100,"bidPrice":112.31,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.216782,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789479000000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1697774400000,"exchange":"NASDAQ","adjPreClose":113.58,"preHourTrading":{"tag":"盘前","latestPrice":112.48,"preClose":113.58,"latestTime":"05:54 EDT","volume":765,"amount":85825.44945,"timestamp":1789466090812,"change":-1.1,"changeRate":-0.009685,"amplitude":0.005459},"postHourTrading":{"tag":"盘后","latestPrice":113.6,"preClose":113.58,"latestTime":"19:30 EDT","volume":47166,"amount":5357398.9908,"timestamp":1789428602689,"change":0.02,"changeRate":0.000176,"amplitude":0.003698},"volumeRatio":1.098380753042727,"impliedVol":0.8562,"impliedVolPercentile":0.4777},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABVX\",,,,,undefined,":{"symbol":"ABVX","floatShares":76455400,"roa":"-44.65%","roe":"-157.07%","lyrEps":-5.675825,"volumeRatio":1.098380753042727,"shares":87054500,"dividePrice":0,"high":117.135,"amplitude":0.033168,"preClose":118.64,"low":113.2,"week52Low":69.81,"pbRate":"19.95","psRate":"1742.01","week52High":148.83,"institutionHeld":0,"latestPrice":113.58,"eps":-5.216782,"divideRate":0,"volume":1156685,"delay":0,"ttmEps":-5.216782,"open":116.66,"prevYearClose":134.855,"prevWeekClose":118.64,"prevMonthClose":111.73,"prevQuarterClose":133.26,"fiveDayClose":114.79,"twentyDayClose":118.96,"sixtyDayClose":100.15,"earningDate":1789920000000,"earningTime":"盘后"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABVX\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"ABVX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":-1.08,"defaultRemindTime":1790020800000,"name":null,"time":"盤後","dateTimestamp":1789963200000,"actualEps":null},{"market":"US","date":"2026-05-22","symbol":"ABVX","fiscalQuarterEnding":"2026/03","expectedEps":-1.07,"name":null,"time":"盤後","type":"earning","dateTimestamp":1779422400000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-03-23","symbol":"ABVX","fiscalQuarterEnding":"2025/12","expectedEps":-1.7,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774238400000,"reportTimeType":"post","actualEps":-1.19},{"market":"US","date":"2025-12-15","symbol":"ABVX","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1765774800000,"reportTimeType":"post","actualEps":-2.45},{"market":"US","date":"2025-09-08","symbol":"ABVX","fiscalQuarterEnding":"2025/06","expectedEps":-0.9,"name":null,"time":"盤後","type":"earning","dateTimestamp":1757304000000,"reportTimeType":"post","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABVX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ABVX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3846,"buy":0.5385,"hold":0.0769,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5385,"analysts":13,"updateTime":1789185600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ABVX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ABVX","date":"2026-09-14","current":-21.772043,"percent":0.262857,"low":-44.789917,"twenty":-27.423187,"median":-6.859493,"eighty":-2.655899,"high":-0.02231,"avg":-14.025904,"sd":12.024317,"marketCap":10023728407.39},"quantilePoints":[{"date":"2023-10-27","current":-7.823172,"twenty":-7.328793,"median":-6.587224,"eighty":-5.845656,"marketCap":753894810.45},{"date":"2023-11-03","current":-6.291292,"twenty":-6.250217,"median":-6.06538,"eighty":-6.010614,"marketCap":611163613.59},{"date":"2023-11-10","current":-6.503512,"twenty":-6.645905,"median":-6.346058,"eighty":-6.06538,"marketCap":637532258.17},{"date":"2023-11-17","current":-7.092251,"twenty":-6.941614,"median":-6.503512,"eighty":-6.069488,"marketCap":704987904.63},{"date":"2023-11-24","current":-6.558278,"twenty":-6.982681,"median":-6.613045,"eighty":-6.085918,"marketCap":654468961.83},{"date":"2023-12-01","current":-6.469283,"twenty":-6.777344,"median":-6.486397,"eighty":-6.085918,"marketCap":645658268.08},{"date":"2023-12-08","current":-6.667811,"twenty":-6.729423,"median":-6.558278,"eighty":-6.270755,"marketCap":658292574.17},{"date":"2023-12-15","current":-6.708886,"twenty":-6.708886,"median":-6.565124,"eighty":-6.291292,"marketCap":675019398.57},{"date":"2023-12-22","current":-6.859493,"twenty":-6.749961,"median":-6.585661,"eighty":-6.304984,"marketCap":690021158.62},{"date":"2023-12-29","current":-6.722577,"twenty":-6.78282,"median":-6.609622,"eighty":-6.321414,"marketCap":681416772.26},{"date":"2024-01-05","current":-6.626736,"twenty":-6.777344,"median":-6.626736,"eighty":-6.346059,"marketCap":664561787.4},{"date":"2024-01-12","current":-6.845802,"twenty":-6.796512,"median":-6.667811,"eighty":-6.407671,"marketCap":685854313.55},{"date":"2024-01-19","current":-7.023793,"twenty":-6.859493,"median":-6.681503,"eighty":-6.435054,"marketCap":698334715.34},{"date":"2024-01-26","current":-7.986412,"twenty":-6.982718,"median":-6.681503,"eighty":-6.435054,"marketCap":792063074.67},{"date":"2024-02-02","current":-8.137618,"twenty":-7.092251,"median":-6.715732,"eighty":-6.469283,"marketCap":807847078.54},{"date":"2024-02-09","current":-7.972666,"twenty":-7.379774,"median":-6.743115,"eighty":-6.503512,"marketCap":785337680.3},{"date":"2024-02-16","current":-7.738985,"twenty":-7.738985,"median":-6.763653,"eighty":-6.503512,"marketCap":761909093.06},{"date":"2024-02-23","current":-8.385046,"twenty":-7.788813,"median":-6.78419,"eighty":-6.508989,"marketCap":829978945.38},{"date":"2024-03-01","current":-8.879901,"twenty":-7.848771,"median":-6.818419,"eighty":-6.548694,"marketCap":878391233.38},{"date":"2024-03-08","current":-8.921139,"twenty":-7.986412,"median":-6.859493,"eighty":-6.569232,"marketCap":892211380.33},{"date":"2024-03-15","current":-8.659965,"twenty":-8.228342,"median":-6.982681,"eighty":-6.577447,"marketCap":863166780.31},{"date":"2024-03-22","current":-9.319772,"twenty":-8.319065,"median":-7.010102,"eighty":-6.584292,"marketCap":926107447.06},{"date":"2024-03-28","current":-9.209804,"twenty":-8.585737,"median":-7.078559,"eighty":-6.597984,"marketCap":910336135.23},{"date":"2024-04-05","current":-9.732151,"twenty":-8.736943,"median":-7.311316,"eighty":-6.610307,"marketCap":967400801.65},{"date":"2024-04-12","current":-5.879845,"twenty":-8.706701,"median":-7.078559,"eighty":-6.566493,"marketCap":928230894.29},{"date":"2024-04-19","current":-6.030284,"twenty":-8.692955,"median":-6.99641,"eighty":-6.48982,"marketCap":950004364.47},{"date":"2024-04-26","current":-6.311356,"twenty":-8.670962,"median":-6.941624,"eighty":-6.433272,"marketCap":998864220.67},{"date":"2024-05-03","current":-5.987697,"twenty":-8.585737,"median":-6.859493,"eighty":-6.311356,"marketCap":946423801.22},{"date":"2024-05-10","current":-5.698107,"twenty":-8.470271,"median":-6.80815,"eighty":-6.289097,"marketCap":907055615.77},{"date":"2024-05-17","current":-5.502208,"twenty":-8.401541,"median":-6.777344,"eighty":-6.21545,"marketCap":883582818.48},{"date":"2024-05-24","current":-5.348896,"twenty":-8.33556,"median":-6.749961,"eighty":-6.06538,"marketCap":855336978.03},{"date":"2024-05-31","current":-5.357413,"twenty":-8.297072,"median":-6.736269,"eighty":-6.030284,"marketCap":858278233.57},{"date":"2024-06-07","current":-5.493691,"twenty":-8.288824,"median":-6.708886,"eighty":-5.988933,"marketCap":883175015.23},{"date":"2024-06-14","current":-5.042271,"twenty":-8.277827,"median":-6.681503,"eighty":-5.938296,"marketCap":801878490.85},{"date":"2024-06-21","current":-5.510725,"twenty":-8.253084,"median":-6.681503,"eighty":-5.777439,"marketCap":872433075.44},{"date":"2024-06-28","current":-4.974132,"twenty":-8.244837,"median":-6.681503,"eighty":-5.74004,"marketCap":786723361.52},{"date":"2024-07-05","current":-5.306309,"twenty":-8.203599,"median":-6.667811,"eighty":-5.629968,"marketCap":847517911.35},{"date":"2024-07-12","current":-5.408517,"twenty":-8.118374,"median":-6.619891,"eighty":-5.595899,"marketCap":868631706.71},{"date":"2024-07-15","current":-5.417034,"twenty":-8.099129,"median":-6.613045,"eighty":-5.590788,"marketCap":873513053.92},{"date":"2024-08-02","current":-4.676203,"twenty":-8.079885,"median":-6.609622,"eighty":-5.583974,"marketCap":745105907.03},{"date":"2024-08-09","current":-4.513478,"twenty":-8.008406,"median":-6.578816,"eighty":-5.515836,"marketCap":727494223.22},{"date":"2024-08-16","current":-4.316495,"twenty":-7.986412,"median":-6.534318,"eighty":-5.490284,"marketCap":700482151.8},{"date":"2024-08-23","current":-4.453526,"twenty":-7.978164,"median":-6.503512,"eighty":-5.44429,"marketCap":730827498.61},{"date":"2024-08-30","current":-4.898879,"twenty":-7.906686,"median":-6.449861,"eighty":-5.413627,"marketCap":801684090.61},{"date":"2024-09-06","current":-4.667638,"twenty":-7.862699,"median":-6.432827,"eighty":-5.36082,"marketCap":764519824.83},{"date":"2024-09-13","current":-3.822511,"twenty":-7.855735,"median":-6.332367,"eighty":-5.335268,"marketCap":748409890.75},{"date":"2024-09-20","current":-3.623827,"twenty":-7.841256,"median":-6.30817,"eighty":-5.285867,"marketCap":716147844.73},{"date":"2024-09-27","current":-3.630961,"twenty":-7.835207,"median":-6.291292,"eighty":-5.156403,"marketCap":720043812.45},{"date":"2024-10-04","current":-3.210083,"twenty":-7.830393,"median":-6.281546,"eighty":-4.898879,"marketCap":627325694.46},{"date":"2024-10-11","current":-2.96041,"twenty":-7.805992,"median":-6.132492,"eighty":-4.671064,"marketCap":573856377.14},{"date":"2024-10-18","current":-3.434789,"twenty":-7.774725,"median":-6.075649,"eighty":-4.6094,"marketCap":659899758.53},{"date":"2024-10-25","current":-3.324219,"twenty":-7.75548,"median":-6.033455,"eighty":-4.49121,"marketCap":637070240.87},{"date":"2024-10-31","current":-3.438356,"twenty":-7.738985,"median":-6.030284,"eighty":-4.463804,"marketCap":662378132.46},{"date":"2024-11-08","current":-3.427655,"twenty":-7.738985,"median":-5.993854,"eighty":-4.429546,"marketCap":655972131.38},{"date":"2024-11-15","current":-3.106647,"twenty":-7.711493,"median":-5.970662,"eighty":-4.328485,"marketCap":583153684.93},{"date":"2024-11-22","current":-3.010345,"twenty":-7.590528,"median":-5.940851,"eighty":-3.765459,"marketCap":560275247.04},{"date":"2024-11-29","current":-2.837956,"twenty":-7.546541,"median":-5.882667,"eighty":-3.688029,"marketCap":531199944.09},{"date":"2024-12-06","current":-2.848666,"twenty":-7.379774,"median":-5.732176,"eighty":-3.623827,"marketCap":534218918.72},{"date":"2024-12-13","current":-2.548806,"twenty":-7.311316,"median":-5.65552,"eighty":-3.566759,"marketCap":474325506.61},{"date":"2024-12-20","current":-2.520248,"twenty":-7.311316,"median":-5.604416,"eighty":-3.452623,"marketCap":464239022.01},{"date":"2024-12-27","current":-2.516678,"twenty":-7.267503,"median":-5.595899,"eighty":-3.437643,"marketCap":465029850.03},{"date":"2025-01-03","current":-2.49883,"twenty":-7.157971,"median":-5.578864,"eighty":-3.421948,"marketCap":454676281.41},{"date":"2025-01-10","current":-2.309632,"twenty":-7.081298,"median":-5.52776,"eighty":-3.400548,"marketCap":421851498.87},{"date":"2025-01-17","current":-2.156736,"twenty":-7.048438,"median":-5.506467,"eighty":-3.355607,"marketCap":393925230.6},{"date":"2025-01-24","current":-2.178161,"twenty":-7.018316,"median":-5.493691,"eighty":-3.318513,"marketCap":402353167.1},{"date":"2025-01-31","current":-2.156736,"twenty":-6.993672,"median":-5.459621,"eighty":-3.135894,"marketCap":398893952.88},{"date":"2025-02-07","current":-2.038902,"twenty":-6.982711,"median":-5.442586,"eighty":-3.053859,"marketCap":375339390.95},{"date":"2025-02-14","current":-2.431685,"twenty":-6.966258,"median":-5.417034,"eighty":-3.014625,"marketCap":450591803.66},{"date":"2025-02-21","current":-2.725249,"twenty":-6.900568,"median":-5.408517,"eighty":-2.924742,"marketCap":505993414.61},{"date":"2025-02-28","current":-2.478798,"twenty":-6.859493,"median":-5.361671,"eighty":-2.877224,"marketCap":457649034.34},{"date":"2025-03-07","current":-2.62524,"twenty":-6.859493,"median":-5.348896,"eighty":-2.848666,"marketCap":504421902.75},{"date":"2025-03-14","current":-1.950178,"twenty":-6.845802,"median":-5.331861,"eighty":-2.792772,"marketCap":375893933.73},{"date":"2025-03-21","current":-2.425222,"twenty":-6.818419,"median":-5.306309,"eighty":-2.725249,"marketCap":466899893.66},{"date":"2025-03-28","current":-2.16502,"twenty":-6.797881,"median":-5.23817,"eighty":-2.643099,"marketCap":411881933.29},{"date":"2025-04-04","current":-1.798189,"twenty":-6.791035,"median":-5.118927,"eighty":-2.598783,"marketCap":350804145.45},{"date":"2025-04-11","current":-1.7874,"twenty":-6.777344,"median":-4.936505,"eighty":-2.541667,"marketCap":352326323.68},{"date":"2025-04-17","current":-1.884502,"twenty":-6.777344,"median":-4.813235,"eighty":-2.527388,"marketCap":377676205.37},{"date":"2025-04-25","current":-2.187427,"twenty":-6.755438,"median":-4.676203,"eighty":-2.49883,"marketCap":437738722.61},{"date":"2025-05-02","current":-2.334934,"twenty":-6.749961,"median":-4.641945,"eighty":-2.473083,"marketCap":464043181.1},{"date":"2025-05-09","current":-2.219807,"twenty":-6.744484,"median":-4.599123,"eighty":-2.430392,"marketCap":441113036.42},{"date":"2025-05-16","current":-1.936126,"twenty":-6.732161,"median":-4.504914,"eighty":-2.406016,"marketCap":381685399.33},{"date":"2025-05-23","current":-1.820966,"twenty":-6.723946,"median":-4.470655,"eighty":-2.350016,"marketCap":362101694.69},{"date":"2025-05-30","current":-1.900139,"twenty":-6.714362,"median":-4.462091,"eighty":-2.329767,"marketCap":380507035.56},{"date":"2025-06-06","current":-2.513168,"twenty":-6.708886,"median":-4.444961,"eighty":-2.329767,"marketCap":534533766.17},{"date":"2025-06-13","current":-1.97798,"twenty":-6.692456,"median":-4.410704,"eighty":-2.276706,"marketCap":425231303.24},{"date":"2025-06-20","current":-1.793505,"twenty":-6.681503,"median":-4.342188,"eighty":-2.264946,"marketCap":382035064.22},{"date":"2025-06-27","current":-2.138541,"twenty":-6.681503,"median":-4.299366,"eighty":-2.248589,"marketCap":464697383.01},{"date":"2025-07-03","current":-2.289493,"twenty":-6.681503,"median":-3.786854,"eighty":-2.248786,"marketCap":500190485.77},{"date":"2025-07-11","current":-2.429597,"twenty":-6.678765,"median":-3.702296,"eighty":-2.250599,"marketCap":527449091.87},{"date":"2025-07-18","current":-2.945587,"twenty":-6.667811,"median":-3.641661,"eighty":-2.25491,"marketCap":634057320.66},{"date":"2025-07-25","current":-23.061864,"twenty":-6.681503,"median":-3.652361,"eighty":-2.257399,"marketCap":5041932651.84},{"date":"2025-08-01","current":-24.891124,"twenty":-6.708886,"median":-3.72013,"eighty":-2.264403,"marketCap":5288723102.26},{"date":"2025-08-08","current":-24.565749,"twenty":-6.748592,"median":-3.822511,"eighty":-2.266806,"marketCap":5307007573.85},{"date":"2025-08-15","current":-24.412019,"twenty":-6.788297,"median":-4.320777,"eighty":-2.26785,"marketCap":5283013491.79},{"date":"2025-08-22","current":-27.056654,"twenty":-6.856755,"median":-4.350753,"eighty":-2.269596,"marketCap":5836300408.78},{"date":"2025-08-29","current":-27.951762,"twenty":-6.982711,"median":-4.432115,"eighty":-2.275271,"marketCap":6054693876.38},{"date":"2025-09-05","current":-31.125324,"twenty":-7.064868,"median":-4.453526,"eighty":-2.278142,"marketCap":6729569738.1},{"date":"2025-09-12","current":-27.34583,"twenty":-7.311316,"median":-4.470655,"eighty":-2.289493,"marketCap":6274864374.63},{"date":"2025-09-19","current":-27.152436,"twenty":-7.738985,"median":-4.492066,"eighty":-2.306579,"marketCap":6253253490.1},{"date":"2025-09-26","current":-27.191115,"twenty":-7.780223,"median":-4.581994,"eighty":-2.309632,"marketCap":6202939418.56},{"date":"2025-10-03","current":-27.92601,"twenty":-7.845289,"median":-4.624816,"eighty":-2.312121,"marketCap":6384002898.09},{"date":"2025-10-10","current":-30.594839,"twenty":-7.986412,"median":-4.667638,"eighty":-2.323665,"marketCap":6912424239.13},{"date":"2025-10-17","current":-30.362767,"twenty":-8.220094,"median":-4.710461,"eighty":-2.327411,"marketCap":6924043391.69},{"date":"2025-10-24","current":-30.633518,"twenty":-8.30257,"median":-4.898879,"eighty":-2.331337,"marketCap":6947674791.64},{"date":"2025-10-31","current":-35.158924,"twenty":-8.659965,"median":-5.080599,"eighty":-2.331337,"marketCap":7943607628.35},{"date":"2025-11-07","current":-34.191957,"twenty":-8.769933,"median":-5.221135,"eighty":-2.334934,"marketCap":7707312075.45},{"date":"2025-11-14","current":-36.435321,"twenty":-8.934885,"median":-5.289274,"eighty":-2.340751,"marketCap":8287572122.24},{"date":"2025-11-21","current":-39.68433,"twenty":-9.168566,"median":-5.331861,"eighty":-2.344168,"marketCap":8947428940.69},{"date":"2025-11-28","current":-41.772979,"twenty":-9.226299,"median":-5.340378,"eighty":-2.351863,"marketCap":9466410187.89},{"date":"2025-12-05","current":-36.473999,"twenty":-9.286782,"median":-5.354345,"eighty":-2.35938,"marketCap":8310882570.26},{"date":"2025-12-12","current":-41.850337,"twenty":-9.520464,"median":-5.382965,"eighty":-2.371798,"marketCap":9611017354.25},{"date":"2025-12-19","current":-26.516104,"twenty":-20.549981,"median":-5.417034,"eighty":-2.383656,"marketCap":9139275129.17},{"date":"2025-12-26","current":-32.349646,"twenty":-23.956328,"median":-5.429811,"eighty":-2.389415,"marketCap":11186696717.72},{"date":"2026-01-02","current":-30.493519,"twenty":-24.259916,"median":-5.455362,"eighty":-2.392505,"marketCap":10512635312.43},{"date":"2026-01-09","current":-26.250942,"twenty":-24.408436,"median":-5.485173,"eighty":-2.400028,"marketCap":8979345802.35},{"date":"2026-01-16","current":-27.099458,"twenty":-24.671496,"median":-5.49795,"eighty":-2.410756,"marketCap":9234075745.3},{"date":"2026-01-23","current":-28.266166,"twenty":-24.923661,"median":-5.514984,"eighty":-2.41264,"marketCap":9748190743.74},{"date":"2026-01-30","current":-25.137266,"twenty":-25.338253,"median":-5.570347,"eighty":-2.413186,"marketCap":8803591875.67},{"date":"2026-02-06","current":-25.694104,"twenty":-25.420854,"median":-5.59164,"eighty":-2.415525,"marketCap":8892505001.77},{"date":"2026-02-13","current":-28.160102,"twenty":-25.842594,"median":-5.604416,"eighty":-2.424554,"marketCap":9808417129.46},{"date":"2026-02-20","current":-29.8041,"twenty":-26.038814,"median":-5.612933,"eighty":-2.425222,"marketCap":10293092752.09},{"date":"2026-02-27","current":-27.205522,"twenty":-26.533578,"median":-5.732176,"eighty":-2.429597,"marketCap":9418925305.5},{"date":"2026-03-06","current":-24.925137,"twenty":-26.516104,"median":-5.879845,"eighty":-2.431685,"marketCap":8459789891.3},{"date":"2026-03-13","current":-26.834297,"twenty":-26.533578,"median":-5.940851,"eighty":-2.439509,"marketCap":9079426835.73},{"date":"2026-03-20","current":-29.008617,"twenty":-26.834297,"median":-5.970662,"eighty":-2.463662,"marketCap":9819639406.07},{"date":"2026-03-27","current":-21.015395,"twenty":-26.834297,"median":-5.993854,"eighty":-2.464511,"marketCap":8146846911.19},{"date":"2026-04-02","current":-23.889698,"twenty":-26.791871,"median":-6.021767,"eighty":-2.473083,"marketCap":9269655072.73},{"date":"2026-04-10","current":-25.421089,"twenty":-26.781265,"median":-6.033455,"eighty":-2.478084,"marketCap":9995412686.01},{"date":"2026-04-17","current":-24.667173,"twenty":-26.643534,"median":-6.075649,"eighty":-2.488644,"marketCap":9762937178.52},{"date":"2026-04-24","current":-22.617465,"twenty":-26.548683,"median":-6.132492,"eighty":-2.497285,"marketCap":8904504345.79},{"date":"2026-05-01","current":-22.723485,"twenty":-26.519599,"median":-6.281546,"eighty":-2.49883,"marketCap":8959888176.91},{"date":"2026-05-08","current":-24.855652,"twenty":-26.431252,"median":-6.291292,"eighty":-2.49883,"marketCap":9832902989.64},{"date":"2026-05-15","current":-23.336041,"twenty":-26.388826,"median":-6.30817,"eighty":-2.5103,"marketCap":9155235319.25},{"date":"2026-05-22","current":-25.110387,"twenty":-26.341097,"median":-6.332367,"eighty":-2.515976,"marketCap":9778300609.43},{"date":"2026-05-29","current":-27.204576,"twenty":-26.452465,"median":-6.430599,"eighty":-2.51882,"marketCap":10531826440.97},{"date":"2026-06-05","current":-21.07515,"twenty":-26.452465,"median":-6.449861,"eighty":-2.524532,"marketCap":8138996627.53},{"date":"2026-06-12","current":-20.403432,"twenty":-26.394129,"median":-6.503512,"eighty":-2.527388,"marketCap":7810578705.92},{"date":"2026-06-18","current":-20.679316,"twenty":-26.366489,"median":-6.510358,"eighty":-2.527388,"marketCap":7884389896.71},{"date":"2026-06-26","current":-20.271488,"twenty":-26.33676,"median":-6.575393,"eighty":-2.530811,"marketCap":7666425554.42},{"date":"2026-07-02","current":-30.659126,"twenty":-26.404736,"median":-6.59593,"eighty":-2.53709,"marketCap":11655941374.46},{"date":"2026-07-10","current":-31.890615,"twenty":-26.746832,"median":-6.626736,"eighty":-2.543095,"marketCap":12110267741.2},{"date":"2026-07-17","current":-30.930523,"twenty":-26.834297,"median":-6.667811,"eighty":-2.55052,"marketCap":11755084937.65},{"date":"2026-07-24","current":-29.269824,"twenty":-26.959814,"median":-6.681503,"eighty":-2.564944,"marketCap":11055640094.37},{"date":"2026-07-31","current":-27.583176,"twenty":-27.075079,"median":-6.681503,"eighty":-2.595213,"marketCap":10549310515.77},{"date":"2026-08-07","current":-29.607153,"twenty":-27.191115,"median":-6.715732,"eighty":-2.598783,"marketCap":11333828453.56},{"date":"2026-08-14","current":-26.649033,"twenty":-27.205522,"median":-6.743115,"eighty":-2.618096,"marketCap":10213208013.38},{"date":"2026-08-21","current":-28.220286,"twenty":-27.205522,"median":-6.763653,"eighty":-2.62524,"marketCap":10949286420.23},{"date":"2026-08-28","current":-27.431695,"twenty":-27.34583,"median":-6.791035,"eighty":-2.632383,"marketCap":10616040493.94},{"date":"2026-09-04","current":-27.488023,"twenty":-27.431695,"median":-6.83211,"eighty":-2.643099,"marketCap":10613111685.26},{"date":"2026-09-11","current":-26.578494,"twenty":-27.424889,"median":-6.859493,"eighty":-2.653339,"marketCap":10266716010.47},{"date":"2026-09-14","current":-26.145577,"twenty":-27.423187,"median":-6.859493,"eighty":-2.655899,"marketCap":10023728407.39}],"updateTime":1789467717988},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ABVX\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1154699591","title":"異動解讀｜Abivax S.A.盤中下跌5.15%，三期試驗安全性爭議未消致反彈行情受阻","url":"https://stock-news.laohu8.com/highlight/detail?id=1154699591","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154699591?lang=zh_tw&edition=fundamental","pubTime":"2026-06-24 22:15","pubTimestamp":1782310523,"startTime":"0","endTime":"0","summary":"6月24日，Abivax S.A.盘中下跌5.15%，报82.65美元/股，成交额7880.38万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后市场部分投资者认为癌症病例更可能与患者年龄相关，前期反应或过度，股价一度反弹至100美元上方。当前股价再度回落，显示市场对安全性争议的分歧尚未完全消化，技术性反弹动能减弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194191893","title":"異動解讀｜Abivax S.A.盤中上漲5.15%，三期試驗安全性爭議消化後股價延續技術性反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=1194191893","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194191893?lang=zh_tw&edition=fundamental","pubTime":"2026-06-17 22:59","pubTimestamp":1781708376,"startTime":"0","endTime":"0","summary":"6月17日，Abivax S.A.盘中上涨5.15%，报102.48美元/股，成交额5767.44万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后部分投资者认为癌症病例更可能与患者年龄相关，前期市场反应或过度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160844250","title":"異動解讀｜Abivax S.A.盤中上漲5.03%，三期試驗安全性爭議消化後股價延續技術性反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=1160844250","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160844250?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 00:25","pubTimestamp":1781540736,"startTime":"0","endTime":"0","summary":"6月16日，Abivax S.A.盘中上涨5.03%，报101.41美元/股，成交额7746.5万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例引发股价自130美元附近暴跌至约70美元，跌幅一度近50%。部分投资者认为癌症病例更可能与患者年龄相关，市场前期反应或过度。当前股价自低位持续回升，反映多空博弈中买方力量阶段性占优。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126571678","title":"異動解讀｜Abivax S.A.盤中下跌5.27%，三期試驗癌症病例安全性爭議疊加證券欺詐調查持續壓制股價","url":"https://stock-news.laohu8.com/highlight/detail?id=1126571678","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126571678?lang=zh_tw&edition=fundamental","pubTime":"2026-06-10 23:01","pubTimestamp":1781103697,"startTime":"0","endTime":"0","summary":"6月10日，Abivax S.A.盘中下跌5.27%，报97.51美元/股，成交额4363.33万美元。Wedbush Securities指出该药面临黑框警告风险上升。此外，The Schall Law Firm已对公司启动证券欺诈调查，聚焦其是否就临床试验结果发布虚假或误导性陈述。双重利空叠加下，安全性争议及法律风险持续压制市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143782210","title":"異動解讀｜Abivax S.A.盤中下跌5.32%，三期試驗癌症病例安全性爭議持續壓制股價","url":"https://stock-news.laohu8.com/highlight/detail?id=1143782210","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143782210?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 22:04","pubTimestamp":1780927474,"startTime":"0","endTime":"0","summary":"6月8日，Abivax S.A.盘中下跌5.32%，报97.13美元/股，成交额5404.34万美元。消息面上，公司此前公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且疗效数据位居同类研究前列，但50mg组出现前列腺癌、乳腺癌、结肠异型增生各一例及多例非黑色素瘤皮肤癌，安全性争议仍未消除。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164583039","title":"異動解讀｜Abivax S.A.盤中下跌5.49%，三期試驗癌症病例安全性爭議持續壓制股價","url":"https://stock-news.laohu8.com/highlight/detail?id=1164583039","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164583039?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 23:19","pubTimestamp":1780672755,"startTime":"0","endTime":"0","summary":"6月5日，Abivax S.A.盘中下跌5.49%，报99.57美元/股，成交额1.28亿美元。消息面上，公司此前公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且疗效数据位居同类研究前列，但50mg组出现前列腺癌、乳腺癌、结肠异型增生各一例，安全性争议仍未消除。Wedbush Securities亦指出obefazimod面临黑框警告风险上升。该股此前盘中一度暴跌超40%后有所反弹，当前再度回落反映安全性隐忧仍在主导市场定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172429889","title":"異動解讀｜Abivax S.A.盤中上漲5.65%，三期試驗因癌症病例引發暴跌後延續反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=1172429889","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172429889?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 22:12","pubTimestamp":1780582369,"startTime":"0","endTime":"0","summary":"6月4日，Abivax S.A.盘中上涨5.65%，报98.405美元/股，成交额1.26亿美元。消息面上，公司此前公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但50mg组出现前列腺癌、乳腺癌、结肠异型增生各一例，该股此前盘中一度暴跌超40%。当前股价延续反弹走势，反映部分资金逢低博弈，但杰富瑞分析师指出癌症相关不良事件将持续压制市场情绪及药物商业化前景，安全性争议仍未消除。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162823209","title":"異動解讀｜Abivax S.A.盤中上漲16.03%，三期試驗因癌症病例引發暴跌後盤中延續反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=1162823209","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162823209?lang=zh_tw&edition=fundamental","pubTime":"2026-06-03 21:37","pubTimestamp":1780493835,"startTime":"0","endTime":"0","summary":"6月3日，Abivax S.A.盘中上涨16.03%，报84.875美元/股，成交额1.39亿美元。当前盘中大幅回升反映部分资金逢低博弈，但杰富瑞分析师指出癌症相关不良事件将持续压制市场情绪及药物商业化前景，安全性争议仍未消除。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175805806","title":"異動解讀｜Abivax S.A.盤前上漲6.21%，三期試驗因癌症病例引發暴跌後盤前延續反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=1175805806","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175805806?lang=zh_tw&edition=fundamental","pubTime":"2026-06-03 16:59","pubTimestamp":1780477145,"startTime":"0","endTime":"0","summary":"6月3日，Abivax S.A.盘前上涨6.21%，报76.9美元/股，成交额413.49万美元。消息面上，公司此前公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但50mg组出现前列腺癌、乳腺癌、结肠异型增生各一例，Wedbush Securities指出obefazimod因恶性肿瘤病例面临黑框警告风险上升。此前该股盘中一度暴跌超40%，当前盘前小幅回升反映部分资金逢低博弈，但安全性争议仍未消除。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132003257","title":"異動解讀｜Abivax S.A.夜盤上漲5.28%，三期試驗因癌症病例引發暴跌後盤後小幅回升","url":"https://stock-news.laohu8.com/highlight/detail?id=1132003257","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132003257?lang=zh_tw&edition=fundamental","pubTime":"2026-06-03 11:07","pubTimestamp":1780456044,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.夜盘上涨5.28%，报76.33美元/股，成交额33.09万美元。消息面上，公司公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但试验数据因癌症病例而变得复杂，Wedbush Securities指出obefazimod因恶性肿瘤病例面临黑框警告风险上升。当前夜盘小幅回升反映部分资金逢低博弈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122300146","title":"異動解讀｜Abivax S.A.盤後上漲5.12%，三期試驗因癌症病例引發暴跌後盤後小幅回升","url":"https://stock-news.laohu8.com/highlight/detail?id=1122300146","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122300146?lang=zh_tw&edition=fundamental","pubTime":"2026-06-03 05:17","pubTimestamp":1780435057,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.盘后上涨5.12%，报76.33美元/股，成交额402.8万美元。消息面上，公司公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但试验数据因癌症病例而变得复杂，市场对安全性数据反应强烈消极。此前纳斯达克交易所因消息未披露对该股实施停牌，恢复交易后股价遭大幅抛售，盘中跌幅一度超40%，反映投资者对药物安全性风险的重新定价，盘后出现小幅回升。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165305488","title":"異動解讀｜Abivax S.A.盤中下跌40.7%，三期試驗數據因癌症病例複雜化引發市場恐慌","url":"https://stock-news.laohu8.com/highlight/detail?id=1165305488","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165305488?lang=zh_tw&edition=fundamental","pubTime":"2026-06-02 21:37","pubTimestamp":1780407466,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.盘中下跌40.7%，报81.915美元/股，成交额3.03亿美元。消息面上，公司公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽然试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但试验数据因癌症病例而变得复杂，市场对安全性数据反应强烈消极。此前纳斯达克交易所因消息未披露对该股实施停牌，恢复交易后股价即遭大幅抛售，反映投资者对药物安全性风险的重新定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161098666","title":"異動解讀｜Abivax S.A.盤前下跌30.12%，三期試驗數據因癌症病例複雜化引發市場恐慌","url":"https://stock-news.laohu8.com/highlight/detail?id=1161098666","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161098666?lang=zh_tw&edition=fundamental","pubTime":"2026-06-02 16:06","pubTimestamp":1780387566,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.盘前下跌30.12%，报88.88美元/股，成交额179.2万美元。消息面上，公司公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽然试验达到主要终点且25mg和50mg两个剂量组均满足相关目标，但有报道称试验数据因癌症病例而变得复杂，市场对安全性数据反应强烈消极。此前纳斯达克交易所因消息未披露对该股实施停牌，恢复交易后股价即遭大幅抛售，反映投资者对药物安全性风险的重新定价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168642211","title":"異動解讀｜Abivax S.A.夜盤下跌25.58%，Obefazimod三期維持試驗達主要終點但市場反應消極","url":"https://stock-news.laohu8.com/highlight/detail?id=1168642211","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168642211?lang=zh_tw&edition=fundamental","pubTime":"2026-06-02 08:02","pubTimestamp":1780358521,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.夜盘下跌25.58%，报96.51美元/股，成交额1.87万美元。消息面上，公司公布其核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽然试验达到了主要终点，25mg和50mg两个剂量组亦满足相关目标，但市场对数据表现反应消极，股价在盘后大幅下挫。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188619399","title":"異動解讀｜Abivax S.A.盤後上漲31.08%，報170.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188619399","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188619399?lang=zh_tw&edition=fundamental","pubTime":"2026-06-02 04:31","pubTimestamp":1780345862,"startTime":"0","endTime":"0","summary":"6月2日，Abivax S.A.盘后上涨31.08%，报170.0美元/股，成交额970.37万美元。Abivax S.A.所在的生物科技行业中，个股中，Revolution Medicines涨0.53%，艾伯维公司跌0.53%，吉利德科学持平，安进涨0.46%，再生元制药公司涨0.22%。Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131761327","title":"異動解讀｜Abivax S.A.盤中上漲5.03%，財報披露現金儲備充裕提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1131761327","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131761327?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 23:16","pubTimestamp":1779808609,"startTime":"0","endTime":"0","summary":"5月26日，Abivax S.A.盘中上涨5.03%，报128.12美元/股，成交额8500.7万美元。消息面上，公司披露截至3月31日持有现金、现金等价物及短期投资4.916亿欧元，基于当前运营假设预计现金跑道可延续至第四季度，资金面充裕缓解了市场对其研发可持续性的担忧。Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155275439","title":"異動解讀 | 現金儲備充裕緩解研發擔憂，Abivax S.A.盤前大漲8.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1155275439","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155275439?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 16:14","pubTimestamp":1779783267,"startTime":"0","endTime":"0","summary":"生物技术公司Abivax S.A.（股票代码：ABVX）今日盘前股价大幅上涨8.26%，表现强劲。消息面上，公司近期披露的财务数据显示，截至3月31日，其持有的现金、现金等价物及短期投资总额达4.916亿欧元。基于当前的运营假设，公司预计其现金跑道可延续至今年第四季度。这一充裕的资金状况有效缓解了市场对其核心药物研发项目可持续性的担忧。此外，市场情绪受到机构看多观点的提振。多数卖方分析师维持对该股的买入评级，并给出了高于当前股价的目标价。市场普遍关注其融资与版税安排对长期现金流路径的积极影响，这共同构成了推动股价在盘前时段显著走高的主要因素。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143487991","title":"異動解讀｜Abivax S.A.盤前上漲9.06%，財報披露現金儲備充裕提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1143487991","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143487991?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 16:07","pubTimestamp":1779782858,"startTime":"0","endTime":"0","summary":"5月26日，Abivax S.A.盘前上涨9.06%，报130.46美元/股，成交额122.15万美元。消息面上，公司披露截至3月31日持有现金、现金等价物及短期投资4.916亿欧元，基于当前运营假设预计现金跑道可延续至第四季度，资金面充裕缓解了市场对其研发可持续性的担忧。Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199128647","title":"異動解讀 | 現金儲備充裕緩解研發擔憂，Abivax S.A.夜盤大漲9.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199128647","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199128647?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 15:35","pubTimestamp":1779780949,"startTime":"0","endTime":"0","summary":"Abivax S.A.（股票代码：ABVX）今日夜盘股价大幅上涨9.85%，表现强劲。消息面上，公司近期披露的财务数据显示，截至3月31日，其持有的现金、现金等价物及短期投资总额达4.916亿欧元。基于当前的运营假设，公司预计其现金跑道可延续至今年第四季度。这一充裕的资金状况有效缓解了市场对其核心药物研发项目可持续性的担忧。此外，市场情绪受到机构看多观点的提振。多数卖方分析师维持对该股的买入评级，并给出了高于当前股价的目标价。市场普遍关注其融资与版税安排对长期现金流路径的积极影响，这共同构成了推动股价在夜盘时段显著走高的主要因素。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132190360","title":"異動解讀｜Abivax S.A.夜盤上漲5.8%，財報披露現金儲備充裕提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1132190360","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132190360?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 08:21","pubTimestamp":1779754894,"startTime":"0","endTime":"0","summary":"5月26日，Abivax S.A.夜盘上涨5.8%，报129.06美元/股。消息面上，公司披露截至3月31日持有现金、现金等价物及短期投资4.916亿欧元，基于当前运营假设预计现金跑道可延续至第四季度，资金面充裕缓解了市场对其研发可持续性的担忧。Abivax Sa是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":43,"code":"91000000","status":"200"}]}}